Targeted Therapies Do Not Increase Cardiovascular Risk in Psoriasis
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
Researchers sought to investigate the effect of targeted therapies on cardiovascular risk in psoriasis and psoriatic arthritis.
Researchers determined the effect of depression and anxiety on disease activity among patients with psoriatic arthritis.
The approval is supported by evidence from adequate and well-controlled studies of Stelara.
The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid arthritis.
In a population-based study, researchers examined the association between psoriatic arthritis and all-cause mortality and leading causes of death.
Researchers studied the immune response to COVID-19 vaccination in patients with psoriatic arthritis receiving treatment with tumor necrosis factor inhibitors.
Researchers determined the association of depression and suicidal ideation with psoriatic arthritis in patients with psoriasis, and assessed whether this association was independent of other comorbidities.
The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or nonbiologic DMARDs.
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
The application is supported by data from two phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2) that assessed upadacitinib in adults with active PsA.